Mabion SA
272
Company Profile
Business description
Mabion SA is a Polish biotechnology company focused on developing and launching modern biotechnology drugs based on monoclonal antibody technology. The drugs developed by the company are targeted treatments, characterized by the drug's ability to recognize the factor causing cancer and interact with this factor only. The company is working on the development of its main priority drug, referred to as the MabionCD20 drug. The therapeutic uses of MabionCD20 are for Non-Hodgkin's lymphoma, Leukemia, and Rheumatoid Arthritis.
Contact
ul. Gen. Mariana Langiewicza 60
Konstantynow Lodzki95-050
POLT: +48 422908210
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
268
Stocks News & Analysis
stocks
The lessons behind the best performing stock over the last 80 years
4 factors that led to the incredible returns of Philip Morris.
stocks
10 of the cheapest global companies with wide moats
These undervalued stocks of high-quality companies could be attractive investments today.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,089.90 | 7.80 | 0.10% |
| CAC 40 | 8,114.35 | 40.37 | 0.50% |
| DAX 40 | 23,339.74 | 185.17 | 0.80% |
| Dow JONES (US) | 41,640.85 | 200.78 | -0.48% |
| FTSE 100 | 8,707.12 | 26.83 | 0.31% |
| HKSE | 24,740.57 | 595.00 | 2.46% |
| NASDAQ | 17,496.77 | 311.89 | -1.75% |
| Nikkei 225 | 37,845.42 | 448.90 | 1.20% |
| NZX 50 Index | 12,076.85 | 189.40 | -1.54% |
| S&P 500 | 5,616.75 | 58.37 | -1.03% |
| S&P/ASX 200 | 7,860.40 | 6.30 | 0.08% |
| SSE Composite Index | 3,429.76 | 3.63 | 0.11% |